National Lab Briefs

Berkeley Bevalac, Three Others Threatened Lawrence Berkeley Lab’s venerable Bevalac accelerator, for 35 years a laboratory centerpiece and the tool for four Nobel Prizes, appears to be the big loser in another national lab’s campaign for a new heavy-ion research facility. A Department of Energy panel has suggested that the Bevalac be phased out in the mid-i 990s in favor of Brookhaven National Lab’s proposed Relativistic Heavy Ion Collider if the department’s nuclear ph

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Lawrence Berkeley Lab’s venerable Bevalac accelerator, for 35 years a laboratory centerpiece and the tool for four Nobel Prizes, appears to be the big loser in another national lab’s campaign for a new heavy-ion research facility. A Department of Energy panel has suggested that the Bevalac be phased out in the mid-i 990s in favor of Brookhaven National Lab’s proposed Relativistic Heavy Ion Collider if the department’s nuclear physics budget does not increase substantially. The working group of the Nuclear Science Advisory Committee was asked to weigh the consequences of “constant budgets” over the next several years, a strong possibility given the multibillion-dollar cost of the agency’s cleanup efforts at its nuclear weapons facilities. NSAC strongly endorsed RHIC construction, and listed three “painful, but acceptable, sacrifices,” says NSF nuclear physics director Karl Erb. Besides phasing out the Bevalac, the panel recommended building the RHIC in six years rather-than five and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies